| Breah Chambers, APRN | |
|
4930 Overland Dr, Lawrence, KS 66049-4132 | |
| (785) 856-0708 | |
| (785) 856-0709 |
| Full Name | Breah Chambers |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 4930 Overland Dr, Lawrence, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1982032926 | NPI | - | NPPES |
| 1982032926 | Other | FAMILY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SF0001X | Clinical Nurse Specialist - Family Health | 2013038983 (Missouri) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 76147 (Kansas) | Primary |
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
Widespread capital freezes and financial shortcomings in the healthcare industry have caused a significant decline in the number of Digital Radiography (DR) and Computed Radiography (CR) purchases. One key challenge faced by the industry has been the lack of capital available for technologies which require high initial investments, such as digital solutions. However, with the economy recovering and funds becoming available to potential buyers, the unit shipment volume is expected to gain momentum in 2011.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
MDA grantees Peter Hedera, a neurologist at Vanderbilt University in Nashville, Tenn., and Nigel Laing, a molecular biologist at the University of Western Australia, were part of a team that identified a fourth gene that, when flawed, leads to distal muscular dystrophy (DD).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Breah Chambers, APRN 4930 Overland Dr, Lawrence, KS 66049-4132 Ph: (785) 856-0708 | Breah Chambers, APRN 4930 Overland Dr, Lawrence, KS 66049-4132 Ph: (785) 856-0708 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
Widespread capital freezes and financial shortcomings in the healthcare industry have caused a significant decline in the number of Digital Radiography (DR) and Computed Radiography (CR) purchases. One key challenge faced by the industry has been the lack of capital available for technologies which require high initial investments, such as digital solutions. However, with the economy recovering and funds becoming available to potential buyers, the unit shipment volume is expected to gain momentum in 2011.
Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ (alglucosidase alfa), produced at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. Lumizyme is the first treatment approved in the United States specifically to treat patients with late-onset Pompe disease.
MDA grantees Peter Hedera, a neurologist at Vanderbilt University in Nashville, Tenn., and Nigel Laing, a molecular biologist at the University of Western Australia, were part of a team that identified a fourth gene that, when flawed, leads to distal muscular dystrophy (DD).
› Verified 8 days ago
Miriam Colleen Slaugh, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 330 Arkansas Suite 120, Lawrence, KS 66044 Phone: 785-841-6540 | |
Dr. Olivia Krampen, DNP, MSN, APRN, FNPC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3211 S Iowa St Ste 100, Lawrence, KS 66046 Phone: 785-505-5475 Fax: 785-505-5326 | |
Melissa Norris, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1112 W 6th St Ste 109, Lawrence, KS 66044 Phone: 785-840-9292 Fax: 785-505-5275 | |
Ms. Margaret Ann Daly, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2415 Massachusetts St, Lawrence, KS 66046 Phone: 785-832-4846 Fax: 785-843-8815 | |
Joshua Scott Simmons, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1312 W 6th St, Lawrence, KS 66044 Phone: 785-841-7297 | |
Amy Baker, APRN-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 3211 S Iowa St Ste 100, Lawrence, KS 66046 Phone: 785-505-5475 Fax: 785-505-5326 | |
Kathy Lynn Ramirez, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 330 Arkansas St Ste 205, Lawrence, KS 66044 Phone: 785-505-5045 |